home / stock / cybn:cc / cybn:cc news

CYBN:CC News and Press, CYBIN INC. From 10/03/23

Stock Information
Company Name: CYBIN INC.
Stock Symbol: CYBN:CC
Market: AQNC
Menu
CYBN:CC CYBN:CC Quote CYBN:CC Short CYBN:CC News CYBN:CC Articles CYBN:CC Message Board
Get CYBN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
CYBN:CC - Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder

- Topline efficacy data expected in Q4 2023 - - Preparations are underway to scale the CYB003 program to a potential Phase 3 study in early 2024 - Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage ...
CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Positive Top-Line Data Gathered from Small Pharma Study

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is giving kudos to Small Pharma Inc., a biotechnology company focused on short-duration, p...

CYBN:CC - Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

- Cybin to acquire Small Pharma Inc. in a previously announced all-share transaction expected to close in Q4 2023, creating an international clinical-stage leader in novel psychedelic therapeutics with the largest IP portfolio in the sector - - Results suggest that SSRIs enhance the effic...

CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Partners with Fluence in Preparation to Advance CYB003 Toward Pivotal Studies

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced an agreement with Fluence, a leading continuing education organi...
CYBN:CC - Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced an agree...

CYBN:CC - Cybin to Participate in the Cantor Global Healthcare Conference

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce t...

CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules Annual Shareholder Meeting

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is making plans for its annual shareholder meeting. The company announced that it has sche...
CYBN:CC - Cybin Announces Date of Annual and Special Meeting of Shareholders

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its...

CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Enrollment in Phase 2 CYB003 Study

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company announced that it has completed enrollment in its phase 2 study of CYB003, a pro...

CYBN:CC - Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

- Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2 data for pivotal studies - - Breakthrough Therapy designation anticipated in late 2023, subject to FDA approval - - P...
Previous 10 Next 10